literature

HIV mutation literature information.

HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.

PMID: 28472323 2017 The Journal of antimicrobial chemotherapy

Table: L234I

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.

PMID: 27124362 2016 Journal of acquired immune deficiency syndromes (1999)

Result: Some of the viruses selected by DOR in culture contained additional mutations: V106A/F227L, V106A/L234I, and V106A/F227L/L234I.

Result: To determine whether there is cross resistance between RPV and DOR and to further compare the overall effectiveness of the compounds, RPV and DOR were screened against the following mutants: V106A, L234I,

Discussion: Mutations at V106, with or without additional secondary mutations (F227L, L234I, and F227L/L234I), caused substantial decreases in susceptibility to DOR.

Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.

PMID: 26626277 2015 Journal of translational medicine

Discussion: The occurrences of polymorphic minor INI-accessory mutations (L74I, T125A, V165I, T206S, L234I and V201I) are similar to previous HIV-1C isolates from South Africa.

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

PMID: 25385110 2015 Antimicrobial agents and chemotherapy

Abstract: In the resistance selection of subtype B virus with DOR, a V106A mutant virus led to two mutation pathways, followed by the emergence separately of either F227L or L234I.

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 20462946 2010 The Journal of antimicrobial chemotherapy

Method: These mutations included: (i) 46 non-polymorphic NNRTI-selected mutations at 28 positions (I94L, A98G, L100I, K101E/H/N/P, K102N, K103H/N/S/T, S105T, V106A/M, E138Q, T139R, I178F, V179F, Y181C/I/V, Y188C/H/L, G190A/C/E/Q/S, H221C/Y, K223T,

PMID: 19203393 2009 Retrovirology

Introduction: Several IN polymorphisms (S24N, D25E, T112I, S119P, T125A, K136Q, V201I, L234I and S283G) were present in all three patients, suggesting that they were readily transmitted.

Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.

PMID: 19881888 2008 Future HIV therapy

Introduction: Other in vitro mutations of unknown clinical significance include V189I, E194G, L234I and T386A.

Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.

PMID: 16616962 2006 Antiviral research

Abstract: A mixture of wild-type and V106V/A or L234L/I mutations were found in the RT of some, but not all compound 3-resistant virus strains.

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

PMID: 16472877 2006 Antiviral research

Abstract: Results also demonstrate that the CPV-resistance associated substitutions Y181C, F227C, F227L and L234I reverse the phenotypic resistance to AZT conferred by the T215Y substitution.

Abstract: Results demonstrate that HIV-1 variants selected at increasing CPV concentrations contained multiple substitutions in diverse patterns including L100I, Y181C, G190E and/or L234I in various combinations with K101R/E, K103T, V106A/I, V108I, E138K, T139K,

S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

PMID: 9624472 1998 Antimicrobial agents and chemotherapy

Abstract: The emergence of S-1153-resistant variants is slower than that for nevirapine, and S-1153-resistant variants contained at least two amino acid substitutions, including F227L or L234I.

Browser Board

Co-occurred Entities

Filtrator